ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2641

Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Jason Springer1, Tanaz Kermani 2, Antoine Sreih 3, Dianne Shaw 4, Kalen Young 5, Cristina Burroughs 6 and Peter Merkel 3, 1Kansas University Medical Center, Kansas, MO, 2University of California Los Angeles, Los Angeles, CA, 3University of Pennsylvania, Philadelphia, PA, 4Vasculitis Foundation, North Carolina, 5Vasculitis Foundation, Kansas City, MO, 6University of South Florida, Tampa, FL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ANCA associated vasculitis, Granulomatosis with Polyangiitis and microscopic polyangiitis, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To provide a feasible and sustainable platform for conducting patient-centered research in vasculitis, a prospective, international, internet-based registry of patients with vasculitis has been established. The aim of this study is to describe the self-reported clinical features of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) from this registry.

Methods: Patients (or caregivers) with different forms of vasculitis can join the web-based registry. All information is self-reported through standardized forms, including type of vasculitis, symptoms at disease onset and later in the disease course, and information regarding how diagnosis was made. For each manifestation, patients can respond with “Yes”, “No”, or “I don’t know”. Only patients with GPA or MPA were included in this analysis. Other analyses demonstrated that in this cohort the accuracy of the self-reported diagnosis of GPA or MPA is > 90%.

Results: The study cohort included 762 patients (68% female) with GPA and 164 patients (81% female) with MPA.

GPA Cohort: 98% of patients reported a physician-confirmed diagnosis. Commonly reported means of diagnosis were combinations of laboratory testing (74%), symptoms (70%), biopsy (62%), and imaging (38%). 562 patients (74%) reported having at least one biopsy, including skin (70 patients), kidney (283 patients), lung (192 patients), nasal/sinus (146 patients), nerve (10 patients), other (36 patients). ANCA was reported in 652/692 (94%) patients who knew their ANCA status. Clinical manifestations at entry into the cohort are summarized in Table 1.

MPA Cohort: 99% of patients reported a physician-confirmed diagnosis. Commonly reported means of diagnosis were combinations of laboratory testing (79%), symptoms (67%), biopsy (77%), and imaging (42%). 131 patients (80%) reported having at least one biopsy, including kidney (103 patients), lung (20 patients), skin (15 patients), nerve (6 patients), and nasal (4 patients). ANCA was reported as positive in 147/153 (96%) patients who knew their ANCA status. Clinical manifestations at entry into the cohort are summarized in Table 1.

Conclusion: In this large cohort patients with a self-reported diagnosis of GPA or MPA, disease manifestations were consistent with each type of ANCA-associated vasculitis. As expected, sinus manifestations were more frequently reported in GPA cohort while renal manifestations were more frequent in the MPA cohort. Given the rarity of these and other vasculitides, conducting some types of research through online registries may provide an efficient alternative to in-person, center-of-excellence clinical trials.


Table 1_VPPRN_pt_characteristics


Disclosure: J. Springer, InflaRx, 9; T. Kermani, None; A. Sreih, Bristol-Meyers Squibb, 3, Bristol-Myers Squibb, 3; D. Shaw, None; K. Young, None; C. Burroughs, None; P. Merkel, Abbvie, 5, AbbVie, 5, AstraZeneca, 2, 5, AstraZeneca,, 2, 5, Biogen, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 2, 5, Celgene, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 5, Genentech/Roche, 2, 5, Genetech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 5, Insmed, 5, Jannsen, 5, Kiniksa, 5, Kypha, 2, TerumoBCT, 2, UpToDate, 7.

To cite this abstract in AMA style:

Springer J, Kermani T, Sreih A, Shaw D, Young K, Burroughs C, Merkel P. Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-of-a-cohort-of-patients-with-a-self-reported-diagnosis-of-granulomatosis-with-polyangiitis-or-microscopic-polyangiitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-of-a-cohort-of-patients-with-a-self-reported-diagnosis-of-granulomatosis-with-polyangiitis-or-microscopic-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology